RECRUITINGOBSERVATIONAL
Prediction Model for Response to Biologics and Small Molecular Agent for UC
Establishment of Prediction Model of Biologics and Small Molecular Agent for Patients With Ulcerative Colitis Using Longitudinal Data
About This Trial
This prospective observational study is going to develop and validate a prediction model of response to biologic agents and small molecular agents for Korean patients with ulcerative colitis.
Who May Be Eligible (Plain English)
Who May Qualify:
- Patients with an established diagnosis of ulcerative colitis based on clinical symptoms, endoscopic features and histopathologic features
- Patients who are going to receive vedolizumab, ustekinumab, or tofacitinib treatment
Who Should NOT Join This Trial:
- Not Korean ethnicity by family history
- Inflammatory Bowel Disease Unclassified
- Patients who already received colectomy due to ulcerative colitis
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Patients with an established diagnosis of ulcerative colitis based on clinical symptoms, endoscopic features and histopathologic features
* Patients who are going to receive vedolizumab, ustekinumab, or tofacitinib treatment
Exclusion Criteria:
* Not Korean ethnicity by family history
* Inflammatory Bowel Disease Unclassified
* Patients who already received colectomy due to ulcerative colitis
Treatments Being Tested
DRUG
Vedolizumab, Ustekinumab, or Tofacitinib
Drug administration and prospective follow-up for evaluating response
Locations (1)
Asan Medical Center
Seoul, South Korea